Citations

Showing 10 of 108094 citations.

Artificial intelligence–derived cardiac ageing is associated with cardiac events post-heart transplantation
Ӧzcan, Ilke , Toya, Takumi , Cohen‐Shelly, Michal , Park, Hyun Woong , Ahmad, Ali , Ozcan, Alp , Noseworthy, Peter A. , Lerman, Lilach O. , Kushwaha, Sudhir S. , Friedman, Paul A. , Ozcan, Ilke , Lerman, Amir , Noseworthy, Peter A , Toya, Takumi , Kapa, Suraj , Attia, Zachi I. , Lerman, Amir

Mayo Clinic

European Heart Journal - Digital Health | September 20, 2022 | Volume: 3 | Issue: 4 | Pages: 516-524

10.1093/ehjdh/ztac051 | PMID 36710906 Get It

AbstractAimsAn artificial intelligence algorithm detecting age from 12-lead electrocardiogram (ECG) has been suggested to reflect ‘physiological age’. An increased physiological age has been associated with a higher risk of cardiac mortality in the non-transplant population. We aimed to investigate the utility of this algorithm in patients who underwent heart transplantation (HTx).Methods and resultsA total of 540 patients were studied. The average ECG ages within 1 year before and after HTx were used to represent pre- and post-HTx ECG ages. Major adverse cardiovascular event (MACE) was defined as any coronary revascularization, heart failure hospitalization, re-transplantation, and mortality. Recipient pre-transplant ECG age (mean 63 ± 11 years) correlated significantly with recipient chronological age (mean 49 ± 14 years, R = 0.63, P < 0.0001), while post-transplant ECG age (mean 54 ± 10 years) correlated with both the donor (mean 32 ± 13 years, R = 0.45, P < 0.0001) and the recipient ages (R = 0.38, P < 0.0001). During a median follow-up of 8.8 years, 307 patients experienced MACE. Patients with an increase in ECG age post-transplant showed an increased risk of MACE [hazard ratio (HR): 1.58, 95% confidence interval (CI): (1.24, 2.01), P = 0.0002], even after adjusting for potential confounders [HR: 1.58, 95% CI: (1.19, 2.10), P = 0.002].ConclusionElectrocardiogram age-derived cardiac ageing after transplantation is associated with a higher risk of MACE. This study suggests that physiological age change of the heart might be an important determinant of MACE risk post-HTx.
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch
Hanson, Sara N. , Arndt, Richard , Speicher, Leigh L. , Seville, Teresa A, Hall, Scott T. , Pike, Marsha L., Heyliger, Alexander , Larsen, Jennifer J., Tulledge‐Scheitel, Sidna M. , Arndt, Richard F, Ganesh, Ravindra , Tulledge-Scheitel, Sidna M, Razonable, Raymund R. , O’Horo, John C. , Ganesh, Ravindra

Mayo Clinic

The Journal of Infectious Diseases | September 20, 2022 | Volume: 226 | Issue: 10 | Pages: 1683-1687

10.1093/infdis/jiac346 | PMID 36124696 Get It

Abstract The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of coronavirus disease 2019 (COVID-19) among older patients, immunosuppressed patients, and those with multiple comorbid conditions. Despite its use in patients with multiple comorbid conditions, the rate of progression to severe disease after bebtelovimab (1.4% [95% confidence interval, 1.2%–1.7%]) was not significantly different from that for nirmatrelvir-ritonavir treatment (1.2% [.8%–1.5%]). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.
Incremental peritoneal dialysis allows to reduce the time spent for dialysis, glucose exposure, economic cost, plastic waste and water consumption
Nardelli, Luca , Scalamogna, Antonio, Cicero, Elisa, Castellano, Giuseppe

Mayo Clinic

Journal of Nephrology | September 20, 2022 | Volume: 36 | Issue: 2 | Pages: 263-273

10.1007/s40620-022-01433-7 | PMID 36125629 Get It

Abstract Background Incremental peritoneal dialysis (incPD) as the initial PD strategy represents a convenient and resource-sparing approach, but its impact on patient, healthcare and environment has not been thoroughly evaluated. Methods This study includes 147 patients who started incPD at our institution between 1st January, 2009 and 31st December, 2021. Adequacy measures, peritoneal permeability parameters, peritonitis episodes, hospitalizations and increase in CAPD dose prescriptions were recorded. The savings related to cost, patient glucose exposure, time needed to perform dialysis, plastic waste, and water usage were compared to full-dose PD treatment. Results During the study follow-up 11.9% of the patients transitioned from incremental to full dose PD. Patient cumulative probability of remaining on PD at 12, 24, 36, 48 and 60 months was 87.6, 65.4, 46.1, 30.1 and 17.5%, respectively. The median transition time from 1 to 2 exchanges, from 2 to 3 and 3 to 4 exchanges were 5, 9 and 11.8 months, respectively. Compared to full dose PD, 1, 2, and 3 exchanges per day led to reduction in glucose exposure of 20.4, 14.8 or 8.3 kg/patient-year, free lifetime gain of 18.1, 13.1 or 7.4 day/patient-year, a decrease in cost of 8700, 6300 or 3540 €/patient-year, a reduction in plastic waste of 139.2, 100.8 or 56.6 kg/patient-year, and a decline in water use of 25,056, 18,144 or 10,196 L/patient-year. Conclusions In comparison with full-dose PD, incPD allows to reduce the time spent for managing dialysis, glucose exposure, economic cost, plastic waste, and water consumption. Graphical abstract
The 50 Most Cited Publications on Concentrated Bone Marrow Aspirate with Application in Orthopaedic Surgery
Oeding, Jacob F. , Hernandez, Hunter , Bi, Andrew S. , Kennedy, John G. , Jazrawi, Laith M. , Oeding, Jacob F , Strauss, Eric J. , Campbell, Kirk A.

Mayo Clinic

The Journal of Knee Surgery | September 19, 2022 | Volume: 36 | Issue: 14 | Pages: 1467-1472

10.1055/a-1946-6981 | PMID 36122693 Get It

AbstractConcentrated bone marrow aspirate (cBMA) has garnered widespread and increasing attention in recent years. We aimed to characterize the most influential articles in cBMA research while clarifying controversies surrounding its use and clinical efficacy and identifying important areas on which to focus future research efforts. The Science Citation Index Expanded subsection of the Web of Science Core Collection was systematically searched to identify the top 50 most cited publications on orthopaedic cBMA research. Publication and study characteristics were extracted, and Spearman's correlations were calculated to assess the relationship between citation data and level of evidence. The top 50 articles were published between the years 1996 and 2018, with 58% published in the year 2010 or later. Of the 29 studies for which level of evidence was assessed, the majority were Level IV (24, 83%). Twenty-one articles (42%) were classified as basic science or translational (9 cell culture, 8 animal study, and 4 using human blood samples). Application to treat cartilage defects was the most common focus of studies (17 studies, 34%), followed by analysis of cBMA composition (14 studies, 28%). No correlation was found between rank, citation rate, or year of publication and level of evidence. The most influential articles on cBMA are recent and consist of a majority low level of evidence studies. Cohort studies were the most common study type among the top 50 most cited articles, while basic science articles were relatively less common. These results suggest a rapidly evolving field with the potential to better explain inconsistent clinical results with improved understanding and documentation of basic science concepts in addition to large-scale, prospective clinical trials. Orthobiologics especially cBMA holds great promise for the future, and higher level clinical trials will help better define the best clinical uses for this treatment.
MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies
Inguanzo, Anna , Przybelski, Scott A. , Diaz‐Galvan, Patricia , Lowe, Val J. , Boeve, Bradley F. , Beek, Marleen van de , Blanc‬, ‪Frederic, Sousa, Paulo Loureiro de , Philippi, Nathalie , Demuynck, Catherine, Nedelská, Zuzana , Oppedal, Ketil , Westman, Eric , Boeve, Brad , Nedelska, Zuzana , Westman, Eric , Inguanzo, Anna , Diaz-Galvan, Patricia , Ferreira, Daniel , Poulakis, Konstantinos , Mohanty, Rosaleena , Schwarz, Christopher G. , Lemstra, Afina W. , Flier, Wiesje M. van der , Barkhof, Frederik , Cretin, Benjamin , Hort, Jakub , Segura, Bàrbara , Junqué, Carme , Aarsland, Dag , Kantarci, Kejal

Mayo Clinic

No container title available | September 19, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2015284/v1 Get It

Abstract Background. Dementia with Lewy bodies (DLB) is a neurodegenerative disorder with a wide heterogeneity of symptoms, which suggests the existence of different subtypes. Objectives. We used data-driven analysis of MRI data to investigate DLB subtypes. Methods. We included 165 probable DLB from the Mayo Clinic and 3 centers from the European DLB consortium and performed a hierarchical cluster analysis to identify subtypes based on gray matter (GM) volumes. To characterize the subtypes, we used demographic and clinical data, as well as β-amyloid and cerebrovascular biomarkers at baseline, and cognitive decline over three years. Results. We identified 3 subtypes: an older subtype with reduced cortical GM volumes, worse cognition, and faster cognitive decline (n=49, 30%); a subtype with low GM volumes in fronto-occipital regions (n=76, 46%); and a subtype of younger patients with the highest cortical GM volumes, proportionally lower GM volumes in basal ganglia and the highest frequency of cognitive fluctuations (n=40, 24%). Conclusions. This study shows the existence of MRI subtypes in DLB, which may have implications for clinical workout, research, and therapeutic decisions.
IRREVERSIBLE RETINAL PIGMENT EPITHELIUM TOXICITY ASSOCIATED WITH FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR THERAPY
Houghton, Odette M.

Mayo Clinic

RETINAL Cases & Brief Reports | September 19, 2022 | Volume: 18 | Issue: 2 | Pages: 214-217

10.1097/icb.0000000000001354 | PMID 36121823 Get It

Purpose: Erdafitinib is a fibroblast growth factor receptor inhibitor indicated for the treatment of cancer. A case of fibroblast growth factor receptor inhibitor–associated retinopathy that resulted in significant visual symptoms and chronic subretinal abnormalities is reported. Methods: A 73-year-old man with a history of relapsed multiple myeloma was treated with erdafitinib. Soon after his fourth treatment cycle, he developed blurred vision in both eyes. Therapy with erdafitinib was subsequently discontinued. Results: Funduscopic examination and optical coherence tomography of both eyes revealed multifocal subretinal fluid in the macula of both eyes. Eleven weeks after cessation of the erdafitinib, the visual acuity improved but the patient reported bilateral annular scotomas. Evaluation was notable for resolution of the subretinal fluid with the development irregular subfoveal thickening in both eyes. The patient's symptoms improved, but the subfoveal abnormalities were persistent at 14 months follow-up. Conclusion: Erdafitinib may be associated with permanent retinal pigment epithelium toxicity.
Imaging of pediatric pulmonary tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper
Thacker, Paul G. , Iyer, Ramesh S. , Pace, Erika , Guillerman, R. Paul , States, Lisa J.

Mayo Clinic

Pediatric Blood & Cancer | September 19, 2022 | Volume: 70 | Issue: S4 | Pages: No page available

10.1002/pbc.29964 | PMID 36121877 Get It

AbstractPediatric pulmonary malignancy can be primary or metastatic, with the latter being by far the more common. With a few exceptions, there are no well‐established evidence‐based guidelines for imaging pediatric pulmonary malignancies, although computed tomography (CT) is used in almost all cases. The aim of this article is to provide general imaging guidelines for pediatric pulmonary malignancies, including minimum standards for cross‐sectional imaging techniques and specific imaging recommendations for select entities.
P16.07: Association Between SARS-CoV-2 Infection and de Novo HLA Donor Specific Antibody Production in Lung Transplant Recipients: Single-Center Study
Elrefaei, Mohamed , Shah, Sadia , Abdelmoneim, Yousif , Pham, Si M. , Shah, Sadia Z.

Mayo Clinic

Transplantation | September 19, 2022 | Volume: 106 | Issue: 9S | Pages: S727-S727

10.1097/01.tp.0000889636.30544.f1 Get It

342.8: Postoperative Statin Therapy Is Not Associated With Reduced Incidence of Venous Thromboembolic Events Following Kidney Transplantation
Frasco, Peter E. , Rosenfeld, David M. , Heilman, Raymond L. , Poterack, Karl A. , Jadlowiec, Caroline C. , Zhang, Nan

Mayo Clinic

Transplantation | September 19, 2022 | Volume: 106 | Issue: 9S | Pages: S324-S325

10.1097/01.tp.0000887148.45038.c8 Get It

310.4: Disparities in Low Respiratory Vaccination Among Solid Organ Transplant Recipients
Felzer, Jamie , Juhn, Young J. , Rutten, Lila J. Finney , Wi, Chung‐Il , LeMahieu, Allison , Beam, Elena , Jacobson, Robert M. , Kennedy, Cassie C.

Mayo Clinic

Transplantation | September 19, 2022 | Volume: 106 | Issue: 9S | Pages: S193-S194

10.1097/01.tp.0000886344.86675.16 Get It